Issue Archive

In a study reported in this Plenary Paper, Dufva and colleagues used functional drug and CRISPR screens to uncover new biology about modulation of responses to chimeric antigen receptor (CAR) T-cell therapy. Their findings suggest that anti-CD19 CAR T-cell therapy can be enhanced through use of small molecules that target death receptor signaling.

In this commissioned Review Series edited and introduced by Associate Editors Bollard and Stevenson, several experts contribute 6 seminal reviews, highlighting cutting-edge developments in the biology and management of primary immune deficiencies.

In this commissioned Review Series edited and introduced by Associate Editors Bollard and Stevenson, several experts contribute 6 seminal reviews, highlighting cutting-edge developments in the biology and management of primary immune deficiencies.

In this commissioned Review Series edited and introduced by Associate Editors Bollard and Stevenson, several experts contribute 6 seminal reviews, highlighting cutting-edge developments in the biology and management of primary immune deficiencies.

In this commissioned Review Series edited and introduced by Associate Editors Bollard and Stevenson, several experts contribute 6 seminal reviews, highlighting cutting-edge developments in the biology and management of primary immune deficiencies.

In this commissioned Review Series edited and introduced by Associate Editors Bollard and Stevenson, several experts contribute 6 seminal reviews, highlighting cutting-edge developments in the biology and management of primary immune deficiencies.

In this commissioned Review Series edited and introduced by Associate Editors Bollard and Stevenson, several experts contribute 6 seminal reviews, highlighting cutting-edge developments in the biology and management of primary immune deficiencies.

Using a novel approach, Vinanica and colleagues revealed that the persistence and efficacy of CAR T-cells in preclinical studies can be enhanced by ectopic expression of a highly active mutant form of the erythropoietin receptor.

Detection of mutant NPM1 measurable residual disease (MRD) in patients with normal karyotype acute myeloid leukemia (AML) after standard therapy portends relapse and is an indication for allografting. Dillon and colleagues now report that the levels of pretransplant NPM1 MRD are highly predictive of posttransplant outcomes, and they propose that high- and low-risk groups can be identified.

Tucker and colleagues report that the recombinant thrombin mutant AB002 (E-WE thrombin) in baboons can rapidly interrupt acute vascular graft thrombus propagation and prevent arterial thrombo-occlusion. Intravenous administration to normal volunteers appears to be safe, leading the authors to recommend its clinical evaluation as a novel antithrombotic.